The grant, entitled Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect warrants up to €1.44 million over 3 years and supports the further ...
PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced ...
Company claims to be the only antibody discovery specialist offering both phage and yeast platforms. Antibody discovery firm AbCheck negotiated nonexclusive rights to Celexion’s Secant™ yeast display ...
AbCheck s.r.o and Pierre Fabre Pharmaceuticals have announced that they have expanded their ongoing collaboration into a strategic research partnership in the field of human antibody discovery and ...
AbCheck s.r.o., has announced the company has licensed a proven antibody yeast display technology from CELEXION LLC (Cambridge, MA, USA). The addition of this platform to AbCheck's current phage ...
PLZEN, Czech Republic and SAN DIEGO, Oct. 30, 2018 /PRNewswire-PRWeb/ -- AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and ...
Czech antibody discovery company AbCheck is now in a research collaboration with Pierre Fabre under which AbCheck will use its AbSieve discovery platform to deliver antibodies against targets provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results